What happened
Kangstem Biotech updated its previously filed consolidated results for FY2025: revenue of US$2.42M (−53.9% year on year), an operating loss of US$12M and a net loss of US$7.09M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$2.42M |
|---|---|
| Revenue vs a year earlier | −53.9% |
| Operating profit | −US$12M |
| Net income | −US$7.09M |
| Period | FY2025 (consolidated) |
| Filed | 2026-03-12, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260312901459 → open original filing |
Versions of this filing
- 2026-01-23Original
- 2026-03-12Amendment 1 (this page)
Source: DART. Information only, not investment advice.